No black box warning on record for Procysbi

As of the latest FDA labeling reviewed, Procysbi (CYSTEAMINE BITARTRATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Procysbi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Ehlers-Danlos-like Syndrome: Reduce dosage if skin and bone lesions occur. ( 5.1 ) Skin Rash: Discontinue if severe skin rash such as erythema multiforme bullosa or toxic epidermal necrolysis occurs. ( 5.2 ) Gastrointestinal (GI) Ulcers and Bleeding: Monitor for GI symptoms and consider decreasing the dose if severe symptoms occur. ( 5.3 ) Fibrosing Colonopathy: Evaluate

No black box warning on record for Procysbi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Ehlers-Danlos-like Syndrome: Reduce dosage if skin and bone lesions occur. ( 5.1 ) Skin Rash: Discontinue if severe skin rash such as erythema multiforme bullosa or toxic epidermal necrolysis occurs. ( 5.2 ) Gastrointestinal (GI) Ulcers and Bleeding: Monitor for GI symptoms and consider decreasing the dose if severe symptoms occur. ( 5.3 ) Fibrosing Colonopathy: Evaluate

Procysbi Black Box Warning

No black box warning on record for Procysbi

Other warnings & precautions

Procysbi Black Box Warning

No black box warning on record for Procysbi

Other warnings & precautions